HBM 9014
Alternative Names: HBM-9014Latest Information Update: 14 Jun 2024
At a glance
- Originator Harbour BioMed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunostimulants; OSM-LIF receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 23 Feb 2023 Harbour BioMed announces intention to submit IND application in 2023
- 21 Feb 2023 Preclinical trials in Solid tumours in China (Parenteral) (Harbor Biomed pipeline, February 2023)